On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Axion Power International, (NASDAQ:AXPW), North American Palladium (NYSEMKT:PAL), Alpha Natural, (NYSE:ANR), BioCryst Pharmaceuticals, (NASDAQ:BCRX), Abraxas Petroleum (NASDAQ:AXAS)
Axion Power International, Inc (NASDAQ:AXPW)’s shares dwindled -13.75%, and closed at $0.0621, hitting new 52-week low of $0.06. The stock volatility for the week is 44.08%, while for the month remained 35.94%.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -4.26diluted EPS growth for trailing twelve months. However, YTD EPS growth remained - 21.80% and Annual EPS growth for the past 5 years is considered as 27.40%.
Axion Power International, Inc. is engaged in the design, development, manufacture, and sale of advanced energy storage devices, components, and systems based on its patented PbC Technology. Its PbC batteries and components are used in energy system storage functions. The company also manufactures standard and specialty lead-acid batteries. Axion Power International, Inc. was founded in 2003 and is based in New Castle, Pennsylvania.
North American Palladium Ltd (USA) (NYSEMKT:PAL), declined -12.32%, and closed at $0.180. The stock has price to sale ratio of 0.48, however, price to book ratio is 0.39. With recent decline, the year-to-date (YTD) performance reflected a 38.46% gain above last year. During the past month the stocks lose -18.18%, bringing three-month performance to 38.46% and six-month performance to -14.29%. The mean recommendation of analysts for this stock is 4.00. (where 1=Buy, 5=Sale).
North American Palladium Ltd. produces precious metals in Canada. It explores for palladium, platinum, nickel, copper, and other metals. It primarily holds interest in the Lac des Iles mine located to the northwest of Thunder Bay, Ontario. The company was founded in 1968 and is headquartered in Toronto, Canada.
Alpha Natural Resources, Inc (NYSE:ANR), dipped -10.00%, and closed at $0.828. The company holds the market capitalization of 183.58M. For the last twelve months, the stock was able to keep return on equity at -25.10%, while return on assets at -7.70%, in response to its return on investment at -12.60%. Its 20-day moving average declined -25.33%, below 50-day moving average of -27.86%, below 200-day moving average of -65.50% from the latest market price of $0.83. The mean recommendation of analysts for this stock is 3.30.(where 1=Buy, 5=Sale).
Alpha Natural Resources, Inc., together with its subsidiaries, engages in extracting, processing, and marketing steam and metallurgical coal in Kentucky, Pennsylvania, Virginia, West Virginia, and Wyoming. It operates through two segments, Eastern Coal Operations and Western Coal Operations. As of December 31, 2014, the company operated 60 mines and 22 coal preparation plants in Northern and Central Appalachia and the Powder River Basin. It also repairs and resells equipment and parts used in surface mining and supporting preparation plant operations; manufactures patented particulate scrubbers and filters for underground diesel engine applications; and rebuilds underground mining equipment.
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX), dropped -7.19%, and closed at $9.49. The stock has the beta value of 2.38, and its volatility for the week is 4.40%, while for the month it is 4.70%. The company has the market capitalization of $686.32M. The company holds the book value per share of 1.05, whereas cash per share is 1.01. Price to book ratio remained 9.04, while price to sale ratio is 50.46. Analysts mean recommendation for the stock is said to be 2.20 (where 1=Buy, 5=sale).
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates comprise peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE.
Abraxas Petroleum Corp (NASDAQ:AXAS), dwindled -6.73%, and closed at $2.91. The stock has price to sale ratio of 2.31, however, price to book ratio is 1.74. With recent decline, the year-to-date (YTD) performance reflected a -1.02 % decline below last year. During the past month the stocks lose - 9.63%, bringing three-month performance to -2.02% and six-month performance to -49.21%. The mean recommendation of analysts for this stock is 2.10. (where 1=Buy, 5=Sale).
Abraxas Petroleum Corporation, an independent energy company, engages in the attainment, exploitation, development, and production of oil and gas properties in the United States. The company operates oil and gas assets in the Rocky Mountain, Permian Basin, and onshore Gulf Coast regions. As of December 31, 2014, its estimated net proved reserves were 42.4 million barrels of oil equivalent. The company was founded in 1977 and is based in San Antonio, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
